Abstract
Objective
Endovascular aortic aneurysm repair has become the principle technique used to treat abdominal aortic aneurysms. However, its long-term success is limited by complications, including type II endoleaks from lumbar arteries and the inferior mesenteric artery. Treatment of these endoleaks can be difficult. The most commonly performed procedure is embolisation via mesenteric or iliolumbar vessels. Embolic agents currently used include coils, glue and Onyx, all of which have their limitations. Our aim was to assess a novel embolic agent precipitating hydrophobic injectable liquid (PHIL) this is currently used in the treatment by neuro-interventionists in the treatment of cerebral arterio-venous malformations.
Methods
Here we describe three patients successfully treated with PHIL.
Results
All three patients had type II endoleaks which were successfully embolised. PHIL displayed favourable embolic characteristics with good distal penetration, rapid injection speed and a lack of glare artefact on follow-up CT.
Conclusion
PHIL is a promising novel embolic agent in the treatment of type II endoleaks, our initial experience has been positive but larger series will be required to evaluate this further.
This is a preview of subscription content, log in via an institution to check access.
References
Chaikof EL, Brewster DC, Dalman RL, et al. SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: executive summary. J Vasc Surg. 2009;50:880–96.
Aziz A, Menias CO, Sanchez LA, et al. Outcomes of percutaneous endovascular intervention for type II endoleak with aneurysm expansion. J Vasc Surg. 2012;55:1263–7.
van Marrewijk CJ, Fransen G, Laheij RJ, et al. EUROSTAR Collaborators. Is a type II endoleak after EVAR a harbinger of risk? causes and outcome of open conversion and aneurysm rupture during follow-up. Eur J Vasc Endovasc Surg. 2004;27:128–37.
Cho JS, Park T, Kim JY, et al. Prior endovascular abdominal aortic aneurysm repair provides no survival benefits when the aneurysm ruptures. J Vasc Surg. 2010;52:1127–34.
Jones JE, Atkins MD, Brewster DC, et al. Persistent type 2 endoleak after endovascular repair of abdominal aortic aneurysm is associated with adverse late outcomes. J Vasc Surg. 2007;46:1–8.
Abularrage CJ, Crawford RS, Conrad MF, et al. Preoperative anatomic variables are predictive of persistent type 2 endoleak after EVAR. J Vasc Surg. 2010;52:19–24.
Kasirajan K, Matteson B, Marek JM, Langsfeld M. Technique and results of transfemoral super selective coil embolization of type II lumbar endoleak. J Vasc Surg. 2003;38:61–6.
Rial R, Serrano F, Vega M, et al. Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac. Eur J Vasc Endovasc Surg. 2004;27:333–5.
Wisselink W, Cuesta MA, Berends FJ, et al. Retroperitoneal endoscopic ligation of lumbar and inferior mesenteric arteries as a treatment of persistent endoleak after endoluminal aortic aneurysm repair. J Vasc Surg. 2000;31:1240–4.
Hinchliffe RJ, Singh-Ranger R, Whitaker SC, Hopkinson BR. Type II endoleak: transperitoneal sacotomy and ligation of side branch endoleaks responsible for aneurysm sac expansion. J Endovasc Ther. 2002;9:539–42.
Faries PL, Cadot H, Agarwal G, et al. Management of endoleak after endovascular aneurysm repair: cuffs, coils, and conversion. J Vasc Surg. 2003;37:1155–61.
Sheehan MK, Barbato J, Compton CN, et al. Effectiveness of coiling in the treatment of endoleaks after endovascular repair. J Vasc Surg. 2004;40:430–4.
Görich J, Rillinger N, Sokiranski R, et al. Embolization of type II endoleaks fed by the inferior mesenteric artery: using the superior mesenteric artery approach. J Endovasc Ther. 2000;7:297–301.
Naveed U. SaqiB, KriStofer M, CharltoN, Ali Azizzadeh Managing type II endoleaks. Endovasc Today. 2013;1:45–50.
Samaniego E, Kalousek V, Abdo G, Ortega-Gutierrez S J. Preliminary experience with Precipitating Hydrophobic Injectable Liquid (PHIL) in treating cerebral AVMs. Neurointerv Surg 2016;8:1253–1255.
Leyon JJ, Chavda S, Thomas A, Lamin S. Preliminary experience with the liquid embolic material agent PHIL (precipitating hydrophobic injectable liquid) in treating cranial and spinal dural arteriovenous fistulas: technical note. J Neurointerv Surg. 2016;8:596–602.
Karthikesalingam A, Thrumurthy SG, Jackson D, et al. Current evidence is insufficient to define an optimal threshold for intervention in isolated type II endoleak after endovascular aneurysm repair. J Endovasc Ther. 2012;19:200–8.
Smith SJ, Thomas A, Ashpole RD. Intra-operative combustion of Onyx embolic material. Br J Neurosurg. 2009;23(1):76–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
No conflicts of interests.
Ethics Statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Helmy, A., Shaida, N. Treatment of Type II Endoleaks with a Novel Agent: Precipitating Hydrophobic Injectable Liquid (PHIL). Cardiovasc Intervent Radiol 40, 1094–1098 (2017). https://doi.org/10.1007/s00270-017-1603-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-017-1603-7